Loading stock data…
MDCX
$0.32-0.02 (-4.64%)
Market OpenUpdated 3:48 PM EDT
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medicus Pharma Ltd. in the Healthcare sector is trading at $0.32 with a market capitalization of $18M. Wall Street consensus targets $5.67 (3 analysts), implying a +1667.5% move over the next 12 months. The stock is currently near its 52-week low of $0.25, remaining 76.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1667.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.32
Potential Downside
0%
Whystock Fair Value$0.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2970.01%
Volume
Today's trading volume
853,542
Recent News
Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix
Medicus Pharma (NASDAQ:MDCX) has filed a substantial modification application through the European Union Clinical Trials Information System to advance a Phase 2b study of its prostate cancer treatment Teverelix, the company said on Monday. The planned trial will focus on patients with...
Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the filing of a registration study with the US Food and Drug Administration (FDA) for its SkinJect program targeting patients with Gorlin syndrome, marking a potentially important step toward commercialization of the...
Medicus Pharma advances SkinJect toward registrational trial for rare Gorlin Syndrome
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a significant regulatory milestone for the company’s SkinJect® program, revealing that Protocol SKNJCT-005 has been submitted to the U.S. Food and Drug Administration under the company’s existing Investigational New Drug (IND) application. The submission is designed to advance SkinJect® into registrational-stage development for patients suffering from Gorlin Syndrome, a rare inherited genetic disorder characterized by the lifelong development of multiple basal cell carcinomas and recurrent skin cancers. Bokhari explained that the filing represents an important step in expanding the clinical development strategy for SkinJect® into an orphan disease indication with substantial unmet medical need. The company believes Gorlin Syndrome presents a compelling opportunity because current treatment options remain limited and there are no FDA-approved lesion-directed therapies specifically developed for patients living with the condition. Gorlin Syndrome is a rare autosomal dominant genetic disorder most commonly caused by mutations affecting the Hedgehog signaling pathway. Individuals diagnosed with the disorder may develop dozens, hundreds, or in some cases more than a thousand skin cancer lesions over their lifetime, requiring ongoing medical intervention and repeated surgical procedures. According to Bokhari, the chronic nature of the disease creates a significant burden on patients, caregivers, and healthcare systems. Repeated surgeries and treatments can lead to scarring, disfigurement, and reduced quality of life, highlighting the need for alternative treatment approaches capable of addressing individual lesions in a more targeted and patient-friendly manner. The company is also pursuing Orphan Drug Designation for the indication, which could provide several important regulatory and commercial benefits if granted by the FDA. These incentives include exemption from FDA new drug application fees, which currently exceed $5 million, as well as seven years of market exclusivity in the United States following regulatory approval. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #GorlinSyndrome #RareDisease #OrphanDrug #Biotech #SkinCancer #ClinicalTrials #DrugDevelopment #HealthcareInnovation
Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted Protocol SKNJCT-005 to the US Food and Drug Administration (FDA) under its existing Investigational New Drug (IND) application for SkinJect, advancing the therapy into registrational development for patients with Gorlin Syndrome, also...
Medicus Pharma secures up to $22M in non-dilutive financing facility
Medicus Pharma (NASDAQ:MDCX) announced on Thursday that it has entered into a definitive financing agreement with an institutional investor for an up to $22 million structured, non-dilutive financing facility aimed at supporting its clinical development programs and extending its cash...